ANMAT Registration Timelines and the Practical Cycle

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Argentina’s official review timelines are tiered by class: Class I/II: 15–30 business days; Class III/IV: 60–110 business days (in practice, commonly 60–120 business days as a practical estimate); IVD Group A/B: 15 administrative business days; IVD Group C/D: 60–90 business days (Group D, because it must include a testing protocol with at least 100 cases, is 110 administrative business days).

Procedurally, after acceptance a formal completeness check of about 10 consecutive days is performed first; applications with incomplete materials receive a single consolidated notification of deficiencies, and the applicant must submit the corrections within 30 business days, with the review clock suspended during the correction period. Once approved, the product is entered into the HELENA public database and receives a PM registration number that can be verified publicly by any downstream party.

Because each tier carries its own clock, the first planning step is to place every product in the correct tier and the correct procedural track — device or IVD, Group A/B or Group C/D. The figures above are administrative business days, not calendar months, and they exclude the correction suspensions described in the following section. Reading them correctly at the start prevents two classic errors: promising delivery dates to commercial teams on the basis of the shortest tier, or applying IVD timelines to devices and vice versa.

2. Legal basis

The instruments below define the review procedures, the tiered timelines and the IVD-specific evaluation requirements.

InstrumentReference / numberPublication dateProvisions
Domestic implementing instrumentDisposición ANMAT 64/2025Published in the Official Gazette on January 13, 2025Review procedure provisions
MERCOSUR technical regulation on medical device registrationGMC/RES 25/21October 13, 2021Part III (procedures and timelines)
IVD registration proceduresDisposición ANMAT 2198/20222022Group C/D review provisions; Group D testing protocol provisions
Good Manufacturing PracticesDisposición ANMAT 3266/20132013BPF certificate procedure provisions

3. Expert insights

Insight 1: the official timeline and the practical end-to-end cycle are two different quantities. The official administrative review window is at most about 110 business days (roughly 5 months), yet the practical end-to-end cycle for Class III/IV is usually 12–15 months or longer. The gap comes from three variables: the time consumed by document preparation and the legalization chain, the number of deficiency rounds, and the scheduling of GMP inspections. Building a project schedule on the official timeline alone is one of the most common budgeting mistakes in Argentina market entry.

Insight 2: the suspension of the clock during corrections affects more than time. Suspension means the waiting period does not count against the official timeline, so ANMAT carries no breach risk; it also means the company’s own correction speed is what actually determines the real cycle. Quality of the deficiency response matters more than raw speed — a second deficiency round can multiply the total cycle several times over.

Insight 3: the verifiability of the PM registration number is an important market-side asset. After approval, the product is entered into the HELENA public database and the registration number can be verified publicly. This serves both as a compliance credential and as the means by which downstream customers and tendering bodies verify suppliers. The accuracy and consistency of the registration number should therefore be managed as part of the company’s market-facing materials.

A realistic schedule treats the official timeline as one component among several. Document preparation, legalization and translation run before filing; the formal check and the review windows run during; and deficiency responses — plus, for Class III/IV, possible GMP inspection scheduling — can extend the tail considerably. The recommendations below organize these components into a plan that can be communicated to commercial teams without creating false expectations about approval dates.

4. Practical recommendations

  1. Schedule on the basis of the official timeline plus a three-variable buffer. Plan 3–6 months for Class I/II (including document preparation and the legalization chain) and 12–15 months for Class III/IV, and reserve buffer for one deficiency round.
  2. Front-load the legalization chain ahead of document preparation. CFS and the apostille and translation of the manufacturer’s authorization are the items most likely to stall the starting point, so they should be initiated first.
  3. Establish a deficiency-response SLA. After receiving an ANMAT deficiency notification, agree internally on the number of days to complete the draft response and the review workflow, so the clock is never suspended indefinitely.
  4. Build a registration-number ledger immediately after approval. Synchronize the PM registration number into the product catalog, distributor materials and tender documents, and periodically reconcile the HELENA database entry.

5. Verification checklist

Confirm each item below before committing dates to customers or internal stakeholders.

  • □ The applicable official review timeline has been confirmed for the product class
  • □ A practical schedule has been built on the three variables (preparation, corrections, GMP scheduling)
  • □ The legalization chain for the CFS and the authorization declaration was initiated before dossier drafting
  • □ An internal deadline commitment for deficiency responses is in place
  • □ A mechanism for reconciling HELENA database entries after approval has been planned
  • □ The PM registration number is included in the product ledger and market-facing materials

Treat this checklist as a living planning document rather than a one-time gate: timelines shift with each deficiency round and each GMP scheduling outcome, and the plan should be re-baselined whenever any of the variables moves. Consistent updates keep commercial commitments aligned with regulatory reality across the full life of the project.

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly-owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly handling classification assessment, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and labeling localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the developments of regulatory authorities worldwide. All published content follows the drafting standard of conclusions first, traceable legal basis, and verifiable figures. For an Argentina or MERCOSUR market-access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail